

# **Global Biosimilar Market Trends & Opportunities: 2015 Edition**

<https://marketpublishers.com/r/G5B4A9C8FAEEN.html>

Date: December 2014

Pages: 80

Price: US\$ 800.00 (Single User License)

ID: G5B4A9C8FAEEN

## **Abstracts**

### Scope of the Report

The report titled “Global Biosimilar Market: Trends & Opportunities (2015 Edition)” analyzes the global biologics market, with exhaustive discussion on demand of Biosimilars with increase in patent expiry of innovator drugs. The key market challenges recognized by the analysts and the major trends biosimilar market are presented in the report. Further, key manufacturers of Biosimilars like Sandoz, Teva, Hospira and Dr. Reddy’s Lab are profiled in the report.

### Product Coverage

Recombinant Glycosylated Biosimilars (EPO,mAb,Follitropin)

Humira, Enbrel, Remicade, Herceptin

Recombinant Non-Glycosylated Biosimilars (Insulin,G-csf,Interferons,hGh)

### Company Coverage

Sandoz(Novartis)

Hospira

Teva

## Dr. Reddy's Lab

### Executive Summary

Rising budgetary pressures to reduce healthcare expenditures, patent expiries of blockbuster drugs, growing demand for cost-effective alternatives, increasing aging population, conducive government initiatives and rising incidences of various diseases are significant factors that are responsible for the growth of global biosimilar market (2013 to 2018). On the other hand stringent regulatory environment in some countries, high manufacturing complexities, costs, and presence of low priced generic drugs and high-entry barriers are considered to hinder the market growth. Emerging pharmaceutical market and less stringent government regulatory frameworks in few countries can provides some of the major opportunities for biosimilars market. In addition, increased collaboration between manufacturing companies and outsourcing of biosimilar products are key trends for biosimilars market.

The biosimilar products market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. Globally there are 280 biosimilars in pipeline and their clinical trials are increasing at a rate of 20% annually.

The report titled “The Global Biosimilar Market: Trends & Opportunities (2014-2018)” provides an in-depth analysis of the growing Biosimilar Market with detailed analysis of market sizing and growth, market share and economic impact of the industry. The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall Biosimilars industry has also been forecasted for the period 2014-18, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. Further, key players of the industry like Sandoz, Teva, Hospira and Dr. Reddy's Lab are profiled.

## Contents

### **1. EXECUTIVE SUMMARY**

### **2. GLOBAL BIOSIMILAR MARKET**

#### 2.1 Overview of Biosimilar Market

- 2.1.1 History
- 2.1.2 Prescription of Biosimilars
- 2.1.3 Naming of Biosimilars
- 2.1.4 Determination of Biosimilarity
- 2.1.5 Differences between Biosimilar and Original Drugs
- 2.1.6 Manufacture of Biosimilars
- 2.1.7 Safety, Efficacy, Quality
- 2.1.8 Variability in Biosimilars
- 2.1.9Regulating Biosimilars
- 2.1.10 Approval Pathways of Biosimilars
- 2.1.11Market Segmentation by Therapeutic Area

### **3. GLOBAL BIOSIMILAR MARKET: SIZING AND GROWTH**

#### 3.1 Biosimilar Market Size: 2009-2013

#### 3.2 Forecasted Biosimilar market Size : 2014-2018

### **4. BIOSIMILAR MARKET ANALYSIS: BY GEOGRAPHY**

#### 4.1 Asia-Pacific

- 4.1.1 China
- 4.1.2 India
- 4.1.3 South Korea, Taiwan, ASEAN
- 4.1.4 Latin America
- 4.1.5 Brazil
- 4.1.6 Mexico
- 4.1.7 Argentina

#### 4.2 Europe

#### 4.3 U.S.A

### **5. BIOSIMILAR MARKET: PRODUCT ANALYSIS**

## 5.1 Recombinant Glycosylated Biosimilars

### 5.1.1 Market Size: 2009-2013

### 5.1.2 Forecasted: 2014-2018

#### 5.1.2.1 Original epoetin (EPO) products

#### 5.1.2.2 Original follitropin product

#### 5.1.2.3 Original Monoclonal antibodies

5.1.2.4 Following are biologic MAb drugs that are expected to become off-patent from 2013 to 2018

## 5.2 Recombinant non-glycosylated proteins

### 5.2.1 Market Size: 2009-2013

### 5.2.2 Forecasted Market Size: 2014-2018

#### 5.2.2.1 Original G-CSF products:

#### 5.2.2.2 Somatotropin Products

## 6. MARKET DYNAMICS OF BIOSIMILAR MARKET

### 6.1 Growth drivers

#### 6.1.1 Patent expiry

#### 6.1.2 Increase in Demand of Biologics

#### 6.1.3 Increase demand to lower the soaring health costs

6.1.4 Focus On Therapeutic Research Areas (Diabetes, Cancer) including Monoclonal Antibody and Human Insulin

#### 6.1.5 Increase in expenditure on biologics globally

### 6.2 Market Challenges

#### 6.2.1 Efficacy issues

#### 6.2.2 Pharmacovigilance

#### 6.2.3 Safety issues

#### 6.2.4 Substitution

#### 6.2.5 Regulatory approval

#### 6.2.6 Barriers to competition

### 6.3 Market trends

#### 6.3.1 Mergers and acquisitions

#### 6.3.2 Penetration into U.S market

## 7. COMPETITIVE LANDSCAPE: GLOBAL BIOSIMILAR MARKET

## 8. COMPANY PROFILES GLOBAL BIOSIMILAR MARKET

### 8.1 Sandoz-Novartis

- 8.1.1 Business overview
- 8.1.2 Financial overview
- 8.1.3 Business strategies
- 8.2 Hospira
  - 8.2.1 Business overview
  - 8.2.2 Financial overview
  - 8.2.3 Business strategies
- 8.3 Teva
  - 8.3.1 Business overview
  - 8.3.2 Financial overview
  - 8.3.3 Business strategies
- 8.4 Dr. Reddy's Laboratories
  - 8.4.1 Business Overview
  - 8.4.2 Financial overview
  - 8.4.3 Business strategies

## Figures & Tables

### LIST OF FIGURES AND TABLES

Figure 1 : Original And Biosimilar Medicine

Figure 2 : Original And Biosimilar Medicine

Figure 3: A stir tank bioreactor

Figure 4: Biosimilars Omnitrope and Accofil

Table 1: List of Biosimilars approved by EMA

Figure 5: Global Biosimilar Market (2009-2013)-sales-U.S\$ Billion

Figure 6: Biosimilar Products Market Share (2013)

Figure 7: Global Biosimilar Market Sales (2014-2018) in U.S\$ Billion

Figure 8: Global biosimilar market share by geography (2013)

Figure 9: Biosimilar uptake across countries in Europe in 2013

Figure 10: Biosimilar Market - Recombinant Glycosylated Products – Sales (2009-2013)  
- US\$ Billion

Figure 11: Biosimilar Market - Recombinant Glycosylated Products – Sales (2014-2018)  
- US\$ Billion

Figure 12: Biosimilar Market –Epoetin and Follitropin– Sales (2014-2018) - US\$ Billion

Figure 13: biosimilar monoclonal antibody market-2013 to 2018-U.S\$ Billion

Table 2: Biosimilars of bevacizumab in development

Table 3: Biosimilars of Adalimumab in development

Table 4: Biosimilar of Entracept Approved for Development

Table 5: Biosimilar of Trastuzumab Approved or in Development

Figure 14: Biosimilar recombinant non-glycosylated Market (2009-2013)- Sales –U.S\$ Billion

Figure 15: Biosimilar recombinant non-glycosylated Market (2014-2018) –Sales-U.S\$ Billion

Figure 16: Biosimilar G-CSF Market (2014-2018)-Sales-U.S\$ Billion

Figure 17: Blockbuster innovator drug market sales-2013-U.S\$ Billion

Table 6: Blockbuster innovator drugs scheduled patent expiries

Figure 18: Global biologics sales and growth: 2009-2013

Table 7: Increase in sales of top six biologic drugs 2012-2013

Figure 19: Potential Cost Savings across Biologic Classes

Figure 20: Core Therapy Areas of biologics Sales-2013-U.S\$ Billion

Figure 21: Mortality rate of cancer patients-2012

Figure 22: Global spending on biologics: 2002-2017-U.S\$ Billion

Table 8: Competitive landscape of key biosimilars players

Figure 23: Global Biosimilar Players market share: 2013

Table 9: characterization of biosimilar players on basis of investmental capabilities and developmental expertise

Figure 24: Sandoz- Biosimilars net revenue: 2011-13 (US\$ Million)

Figure 25: Hospira Net Revenue: 2011-13 (US\$ Million)

Figure 26: Teva's net revenue of oncology and women health products: 2011-13 (US\$ Million)

Figure 27: Dr. Reddy's Lab's Proprietary Products Net Revenue: 2011-14 (US\$ Million)

## I would like to order

Product name: Global Biosimilar Market Trends & Opportunities: 2015 Edition

Product link: <https://marketpublishers.com/r/G5B4A9C8FAEEN.html>

Price: US\$ 800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G5B4A9C8FAEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970